Common variants in MMP20 at 11q22.2 predispose to 11q deletion and neuroblastoma risk.
Nat Commun. 2017 Sep 18;8(1):569
Authors: Chang X, Zhao Y, Hou C, Glessner J, McDaniel L, Diamond MA, Thomas K, Li J, Wei Z, Liu Y, Guo Y, Mentch FD, Qiu H, Kim C, Evans P, Vaksman Z, Diskin SJ, Attiyeh EF, Sleiman P, Maris JM, Hakonarson H
Cell-Cycle Position of Single MYC-Driven Cancer Cells Dictates Their Susceptibility to a Chemotherapeutic Drug.
Cell Syst. 2017 Aug 23;:
Authors: Ryl T, Kuchen EE, Bell E, Shao C, Flórez AF, Mönke G, Gogolin S, Friedrich M, Lamprecht F, Westermann F, Höfer T
Deletion of 11q in neuroblastomas drives sensitivity to PARP inhibition.
Clin Cancer Res. 2017 Aug 22;:
Authors: Sanmartín E, Muñoz L, Piqueras M, Sirerol JA, Berlanga P, Cañete A, Castel V, Font de Mora J
Abstract PURPOSE: Despite advances in multimodal therapy, neuroblastomas with hemizygous deletion in chromosome 11q (20-30%) undergo consecutive recurrences with poor outcome.
Neuroscientists have uncovered the genetic basis for why many long-term survivors of childhood cancer develop meningiomas, the most common adult brain tumour, decades after their treatment with cranial radiation.
Neuroscientists have uncovered the genetic basis for why many long-term survivors of childhood cancer develop meningiomas, the most common adult brain tumour, decades after their treatment with cranial radiation.
The findings, published online today in...
Neuroblastoma is a pediatric cancer characterized by variable outcomes ranging from spontaneous regression to life-threatening progression. High-risk neuroblastoma patients receive myeloablative chemotherapy with hematopoietic stem-cell transplant followed by adjuvant retinoid differentiation treatment. However, the overall survival remains low; hence, there is an urgent need for alternative therapeutic approaches. One feature...
NCI-COG Pediatric MATCH trial to test targeted drugs in childhood cancers Posted: July 24, 2017 240-760-6600 Credit: National Cancer Institute Today investigators at the National Cancer Institute (NCI) and the Children’s Oncology Group (COG) announced the opening of enrollment for a unique precision medicine clinical trial.
The nationwide precision medicine trial will enroll children and adolescents with advanced cancers that haven’t responded to standard therapy to explore treatments targeted at specific genetic mutations.
Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis.
Genes Chromosomes Cancer. 2017 Jan;56(1):28-41
Authors: Marrano P, Irwin MS, Thorner PS
Abstract Amplification of the MYCN gene in neuroblastoma is associated with a poor prognosis and is considered to remain unchanged in post-treatment specimens and metastases.
Using droplet digital PCR to analyze MYCN and ALK copy number in plasma from patients with neuroblastoma.
Oncotarget. 2017 Jul 07;:
Authors: Lodrini M, Sprüssel A, Astrahantseff K, Tiburtius D, Konschak R, Lode HN, Fischer M, Keilholz U, Eggert A, Deubzer HE
Shallow whole genome sequencing on circulating cell-free DNA allows reliable non-invasive copy number profiling in neuroblastoma patients.
Clin Cancer Res. 2017 Jul 14;:
Authors: Van Roy N, Van der Linden M, Menten B, Dheedene A, Vandeputte C, Van Dorpe J, Laureys G, Renard M, Sante T, Lammens T, De Wilde B, Speleman F, De Preter K
Combined epigenetic and differentiation-based treatment inhibits neuroblastoma tumor growth and links HIF2α to tumor suppression.
Proc Natl Acad Sci U S A. 2017 Jul 10;:
Authors: Westerlund I, Shi Y, Toskas K, Fell SM, Li S, Surova O, Södersten E, Kogner P, Nyman U, Schlisio S, Holmberg J
Conditions : Advanced Malignant Solid Neoplasm; FGFR1 Gene Mutation; FGFR2 Gene Mutation; FGFR3 Gene Mutation; FGFR4 Gene Mutation; Histiocytosis; Recurrent Central Nervous System Neoplasm; Recurrent Childhood Non-Hodgkin Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Neuroblastoma; Refractory Central Nervous System Neoplasm; Refractory Malignant Solid Neoplasm; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Stage III Childhood Non-Hodgkin Lymphoma; Stage IV Childhood Non-Hodgkin Lymphoma Interventions : Other: Laboratory Biomarker Analysis; Drug: pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493; Other: Pharmacological Study Sponsor : National Cancer Institute (NCI) Not yet recruiting - verified June 2017
Assessment of Anti-Tumor Cytotoxic Activity of Naturally Occurring Antibodies in Human Serum or Plasma.
Methods Mol Biol. 2017;1643:105-110
Authors: Schwartz-Albiez R, Dill O
Abstract A small percentage of the Western population carries antibodies in the peripheral blood, which are able to kill human tumors such as neuroblastoma or melanoma. Several observations indicate that these antibodies, preferentially of IgM isotype, belong to the class of naturally occurring antibodies.
The functional variant rs34330 of CDKN1B is associated with risk of neuroblastoma.
J Cell Mol Med. 2017 Jun 30;:
Authors: Capasso M, McDaniel LD, Cimmino F, Cirino A, Formicola D, Russell MR, Raman P, Cole KA, Diskin SJ
Abstract The genetic aetiology of sporadic neuroblastoma is still largely unknown.
Neuroblastoma in children: Update on clinicopathologic and genetic prognostic factors.
Pediatr Hematol Oncol. 2017 Jun 29;:1-21
Authors: Ahmed AA, Zhang L, Reddivalla N, Hetherington M
Abstract Neuroblastoma is the most common extracranial solid tumor in childhood accounting for 8-10% of all childhood malignancies. The tumor is characterized by a spectrum of histopathologic features and a heterogeneous clinical phenotype.
Genetic variations appear to pre-dispose children to developing certain severe forms of neuroblastoma, according to new research by the University of Chicago Medicine.
The findings lay the groundwork for developing more targeted treatments for...
Genetic variations appear to pre-dispose children to developing certain severe forms of neuroblastoma, according to new research. The findings lay the groundwork for developing more targeted treatments for particularly deadly variations of the cancer.
The Pediatric Cancer Working Group of the AACR released its first consensus screening guidelines for children with common cancer predisposition syndromes.
( University of Chicago Medical Center ) Genetic variations appear to pre-dispose children to developing certain severe forms of neuroblastoma, according to new research by the University of Chicago Medicine. The findings lay the groundwork for developing more targeted treatments for particularly deadly variations of the cancer.
Genomic analysis-integrated whole-exome sequencing of neuroblastomas identifies genetic mutations in axon guidance pathway.
Oncotarget. 2017 May 23;:
Authors: Li Y, Ohira M, Zhou Y, Xiong T, Luo W, Yang C, Li X, Gao Z, Zhou R, Nakamura Y, Kamijo T, Kaneko Y, Taketani T, Ueyama J, Tajiri T, Zhang H, Wang J, Yang H, Yin Y, Nakagawara A
PHILADELPHIA — The American Association for Cancer Research (AACR) has published its first set of consensus screening recommendations for children with common cancer predisposition syndromes in Clinical Cancer Research, a journal of the AACR. These recommendations emerged from the Childhood Cancer Predisposition Workshop held by the AACR Pediatric Cancer Working Group in October 2016.
Common variants upstream of MLF1 at 3q25 and within CPZ at 4p16 associated with neuroblastoma.
PLoS Genet. 2017 May 18;13(5):e1006787
Authors: McDaniel LD, Conkrite KL, Chang X, Capasso M, Vaksman Z, Oldridge DA, Zachariou A, Horn M, Diamond M, Huo C, Iolascon A, Hakonarson H, Rahman N, Devoto M, Diskin SJ
A new study has served to identify some genetic mutations that will help to improve the treatment of neuroblastoma.